SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset”) today announced that its Tablo® Hemodialysis System has received the first-ever approval from the Centers for Medicare ...
Outset Medical is dedicated to technology-driven service model innovation aimed at reducing cost and transforming the patient care experience. Outset’s Tablo System is FDA-cleared for use in acute, ...
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “company”) today announced it has implemented a shipment hold on the distribution of its Tablo Hemodialysis System ...
SAN JOSE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and ...
SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis ...
Please provide your email address to receive an email when new articles are posted on . Outset Medical, maker of the Tablo hemodialysis machine, reported that the device was added to 30 new hospital ...
After kicking off the year by shipping out a record number of its Tablo hemodialysis systems for at-home users, Outset Medical has brought those sales to a screeching halt. The California-based ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Outset Medical’s Tablo Hemodialysis System for use in a home setting after positive results ...
SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis, announced today that the U.S. Food and Drug ...
Gaeta provided 2026 revenue guidance of "$125 million to $130 million, a 5% to 9% increase over 2025." She expects "the first quarter to be roughly flat to the fourth quarter of 2025, and then ...
Outset Medical announced a hold on shipments of its Tablo dialysis system to home users. This hold will be in place until the FDA completes its review of a new regulatory filing. Outset's revenue will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results